There are both HIV-serodiscordant couple data and population data to support HIV plasma viral load and stage of HIV infection in HIV transmission [15,28,29]. For male circumcision, HIV-serodiscordant couple data are not available; however, three RCTs confirmed unequivocally that it is protective for heterosexual HIV-negative men [24–26]. Pregnancy has been associated with HIV acquisition in a HIV-serodiscordant study  but not in a cohort study . Despite no data from HIV-serodiscordant studies, a large meta-analysis of 19 clinical studies showed a strong association of seropositive HSV-2 serology with HIV acquisition .
A role for GUD in HIV acquisition and transmission was found in two out of three HIV-serodiscordant studies [11,12,15] and a large meta-analysis of 25 heterosexual cohorts . Although HSV-2 seroconversion is associated with HIV acquisition in a cohort study , it was not included as a factor as there were no data from HIV-serodiscordant studies, longitudinal testing for HSV-2 is not routine practice and there is an overlap with GUD which is an independent risk factor in the risk score.
The role of bacterial STI in HIV transmission is complex and lacks consistent agreement between studies. Two large HIV-serodiscordant couples studies found no association of any individual STI with HIV transmission; however, incident rates of STI in these studies was low [11,12]. In contrast, the majority of cohort studies have shown an association of STI, in particular gonorrhoea and Trichomonas vaginalis, with HIV transmission. Gonorrhoea was not associated with HIV transmission in two HIV-serodiscordant studies [11,12] but was associated with HIV acquisition in three cohort studies [14,33,34]. Trichomonas was not associated with HIV transmission in two HIV-serodiscordant studies [11,12] and one cohort study  but was associated with HIV acquisition in two further cohort studies [36,37]. Two cohort studies have shown nonconcordant results in an association of infections syphilis with HIV acquisition [14,38]; however, GUD, the primary stage of the infection, is associated with acquisition [12,31]. For HIV infectiousness the affect appears to be mediated by an increase in plasma viral load (pVL) . Chlamydia was not associated with HIV transmission in two HIV-serodiscordant studies [11,12] and one cohort study  but was associated in three further cohort studies [32,35,40]. In addition, several large, well conducted trials of enhanced STI treatment and care have failed to show a consistent impact on HIV incidence [15,41–43]. Bacterial vaginosis was not associated with HIV acquisition in two HIV-serodiscordant couple studies [11,12] but was significant in two cohort studies [44,45]. Neither genital warts [14,46] nor Candida  have been associated with HIV transmission.
In regard to hormonal influences, the combined oral contraceptive (COCP) was not associated with HIV acquisition in a HIV serodiscordant or a cohort study [30,48] and the depot medroxyprogesterone acetate (DMPA) was not associated with HIV acquisition in two cohort studies [49,50]. Breast feeding was not associated with HIV acquisition in a HIV-serodiscordant couple study .
The estimates are, however, limited by the fact that the majority of anal intercourse estimates derive from MSM cohorts, with little data for anal intercourse amongst heterosexuals. In addition, estimates are not stratified according to HIV-infected partner viral load. However, as the majority of sex act HIV transmission studies were carried out prior to the widespread availability of ART, estimates obtained can be assumed to correspond to an ‘average’ or mean viral load set point of a chronically HIV-infected untreated individual [65–67].
To incorporate the effect of viral load on transmission risk per sex act, we had to adjust for the relative risks calculated for different viral loads assuming transmission estimates for type of sex act represented the risk for an ‘average’ viral load. A set point viral load calculated by Mei et al. was used for the risk score. This estimate derived from individuals prospectively evaluated from primary HIV infection and the data were analysed using four methodologies and calculated a mean viral load set point of 4.20 Log10 copies/ml . For the risk score, the viral load category containing 4.20 Log10 copies/ml  was used as a reference point for the typical viral load of participants in studies that measured the transmission risk associated with different types of sex act.
By incorporating the biological and behavioural risk score, an overall evaluation of exposure is obtained.
Biological factors discussed are incorporated into the model as ‘risk multipliers’, represented by α, with subscripts denoting the particular factor. If a particular condition applies, then the multiplier takes the appropriate value determined from the literature; if the condition does not apply then the multiplier takes the value 1, so that the per-sex-act risk is not modified. Missing values were scored as 1.
For a single unprotected sex act, the risk of transmission is the product of the ‘baseline’ transmission probability for that type of sex act and the relevant risk-modifier coefficients (i.e. HIV viral load category, STI co-infection status), that is
When a risk multiplier does not affect a particular sex-act type it takes the value 1 so it does not affect the calculated risk – this is why multipliers for the effects of both pregnancy and circumcision on susceptibility appear in the generic formula, despite it being impossible for them to apply to the same individual.
When the number of unprotected sex acts exceeds 1, to calculate the risk of acquisition, it is necessary to consider the ‘escape probability’. The ‘escape probability’ is the probability of not becoming infected, which, for a single unprotected sex act, is 1 minus the per-act transmission probability. The escape probability for several sex acts of the same type with the same partner is the escape probability for a single act of that type with that partner raised to the power of the number of acts of that type. The risk of acquisition during those sex acts is 1 minus the total escape probability (as there are only two outcomes – acquiring infection or escaping it – the probability of those two outcomes must sum to 1). Therefore, the risk of HIV acquisition over all unprotected sex acts of a particular type with an HIV-infected partner is the following:
When a person has different types of unprotected sex acts with one partner, the escape probability for all sex acts of all types is the product of the escape probabilities for each type of sex act (considering the number of sex acts of each particular type). The transmission probability for all unprotected sex acts of all types with that partner is 1 minus the escape probability for all sex acts of all types, that is
These formulae apply to having one HIV-positive partner. When an individual has more than one HIV-infected sexual partner, the escape probabilities must be calculated for each partner and then multiplied together to calculate the escape probability for all sex acts of all types with all partners. The risk of acquisition is then 1 minus the escape probability for all sex acts of all types with all HIV-positive partners.
For example, for an uninfected man with an HIV-infected male partner and an HIV-infected female partner, the risk of HIV acquisition is,
where the number of unprotected acts of insertive anal intercourse with the female and males partners, respectively, are NIAI,F and NIAI,M.
Characteristics of the partner(s) that affect the risk score may not always be known. If the partner is known to be HIV-positive then there is a transmission risk, but if the status of the partner with respect to viral load, stage of HIV infection and GUD are not known then the multipliers can be varied between their values if present and 1 (the value if absent) to calculate the range of uncertainty in the estimate of risk that arises from the lack of information. Figure 1 shows a plot of possible scenarios using the HIV risk score and illustrates the range of variation in risk estimates obtained. If it is not known if the partner is HIV-infected or not then this additional uncertainty can be accounted for by estimating the probability that the partner is infected, given the prevalence in the relevant local population group.
In this study we present a formularized approach to synthesizing findings from HIV transmission studies (in particular HIV-serodiscordant couple studies) with potential practical applications. The model enables estimation of an individual's risk of HIV acquisition based on reported sexual practises, STI status and partners infectiousness. As such it could be used as an adjunct in safe sex counselling, for both HIV-infected and uninfected individuals to guide couple-specific evidence-based risk reduction practices and direct the provision of PEP. Importantly it may also inform on the debate in the field of HIV-serodiscordant couple studies by providing a clear definition of exposure; without such a tool comparisons between studies have been impossible. The behaviour score also enables comparison of uninfected unexposed control couples of studies to match sexual practices.
As a transmission model, a Bernoulli model is easily described and manipulated, requires few parameters, has clinical relevance and has been empirically verified in an HIV seroconversion study in Africa . However, as with any model, there are limitations due to its assumptions and supporting data. Firstly, the model assumes that all viral loads have a transmission risk, rather than a threshold below which no transmission is possible. This concurs with models of HIV transmission  and reports of sexual and vertical transmission occurring from individuals with an undetectable viral load [70,71] but contrasts with two studies of HIV-serodiscordant couples, in which no transmission events occurred with viral load below 1500 copies/ml both on ART and ART naive [72,73]. However, the absence of transmission in a study does not rule out the possibility of a low transmission risk. Mathematical models suggest that although the risk of transmission on effective suppressive ART is not zero it is very low . The exact risk of transmission between HIV-serodiscordant couples is currently under investigation in the International Partners study .
Secondly, the model assumes that only a limited number of factors affect susceptibility to HIV infection. This is untrue given the multiple mechanisms contributing to HIV susceptibility (genetic [7,8] and biological  and infectiousness (viral phenotype, load and stage of infection [11,15,16]); if such risks are quantified then they can be incorporated into the model providing the status of the individual which is known. Specifically in the context of HIV-serodiscordant research in which evaluation of CCR5 haplotype of the exposed uninfected and viral co-receptor phenotype of the HIV-infected individual may be available, manipulation of the model could more accurately reflect HIV transmission risk. Finally, due to a lack of data available, the model assumes that all risk factors are independent co-factors of HIV transmission and that the presence of a co-factor affects equally all relevant types of sex act. It was not able to specifically evaluate sex or infection-site-specific (i.e. pharynx, rectum or urethra) risks for incident STI, except for HSV-2 seropositivity  and was also unable to account for interactions of STI, circumcision status and genital tract HIV viral load on HIV infectivity. As such the viral load transmission data used in the risk score were derived from vaginal sex within HIV-serodiscordant couples in Africa  and therefore may not be directly applicable to non-African settings or MSM. To enhance the accuracy of the model more data are required on the role of HIV co-factors specifically within MSM populations, the impact of site-specific STI and the possible amplifying effects of biological co-factors.
In order to ensure that robust data were used to develop the HIV risk model an in-depth literature review was carried out and in contrast to previous publications this review focused on both MSM and heterosexual transmission of HIV. [31,75,76] Effort was made to identify confounding factors, such as HIV viral load, heterogeneity in study design, differences in population characteristics, including STI rates, circumcision rates and sexual behaviour and/or insufficient power due to small sample size. Many studies (especially cross-sectional studies) are limited by the use of historical data as a proxy HIV acquisition, a lack of sexual behaviour data and an inability to detect the co-transmission of HIV and STI. Hence such studies conferred lower priority in developing the risk score.
Studies of HIV-serodiscordant couples were prioritized as they are able to assess the effect of STI on both the infectiousness and susceptibility to HIV, whilst controlling for infectivity mediated via plasma viral load, sex act type and sex frequency. It is accepted, however, that all estimates are affected by unadjusted inclusion of condom-protected acts in the count of sex acts.
The HIV risk score may underestimate risk for a number of reasons: Firstly, the exclusion of bacterial STI; secondly, the lack of information concerning actual risk per site; thirdly the potential for two factors to exponentially increase transmission risk; fourthly, the use of plasma viral load as a surrogate for genital tract HIV viral load. The fact that different ART agents have differential penetration into genital tract mucosae  means that the two sites may reflect one another and has contributed towards the controversy surrounding the Swiss statement . Finally, the viral load set point used in the model (4.2 RNA copies/ml) fits into the second highest viral load category in the Quinn et al. transmission data (4.17–4.88 RNA copies/ml). This means that viral load up to 0.68 Log10 higher are categorized as set point (i.e. transmission risk, which may lead to further underestimation in HIV transmission risk).
The accuracy of the HIV exposure risk score is dependent on the quality of the sexual behaviour information collected (e.g. over-reporting of coital frequency leads to over-estimation of the overall risk) and the quality of the STI screens performed. Further work is underway to elucidate accurate sexual behaviour information in a format appropriate to the model and acceptable to participants .
Validation and assessment of the practical utility of the HIV exposure risk score is required from prospective cohorts of heterosexual  (e.g. HPTN052 study) and MSM HIV-serodiscordant couples. In testing the model, sensitivity analysis will need to be carried out to quantify uncertainty in calculated individual risk arising from uncertainty in parameter estimates from literature (represented by 95% CIs) and uncertainty in the reported behaviour of individuals . Subsequently, the score has potential to be used both in HIV research and HIV (both primary and secondary) prevention. It could also be modified to incorporate partners of known HIV status but unknown HIV viral load using population data (on ART usage, HSV-2 seroprevalence, circumcision status, and STI rates) to numerate the algorithm.
J.F.: model design, manuscript; P.J.W.: model design, manuscript; J.W.: manuscript; G.G.: model design, manuscript; H.W.: model design, manuscript; S.F.: model design, manuscript.
P.J.W. and G.G. thank the Medical Research Council for Centre funding.
3. Guthrie BL, de Bruyn G, Farquhar C. HIV-1-discordant couples in sub-Saharan Africa: explanations and implications for high rates of discordancy. Curr HIV Res 2007; 5:416–429.
4. Sullivan PS, Salazar L, Buchbinder S, Sanchez TH. Estimating the proportion of HIV transmissions from main sex partners among men who have sex with men in five US cities. AIDS 2009; 23:1153–1162.
5. Lattimore S, Thornton A, Delpech V, Elford J. Trends in sexual behaviour among London gay men between 98 and 08
. In Proceedings of the International Society for Sexually Transmitted Diseases Research (ISSTDR) Conference
; June 2009; London.
6. Stolte IG, Dukers NH, Geskus RB, Coutinho RA, de Wit JB. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 2004; 18:303–309.
7. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al
. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367–377.
8. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al
. 1996 Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722–725.
9. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, et al
. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1:59–64.
10. Nicolosi A, Corrêa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A, et al
. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Epidemiology 1994; 5:570–575.
11. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al
. 2000 Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group
. N Engl J Med342
12. Gray RH, Wawer MJ, Brookmeyer R, Rakai Project Team. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149–1153.
13. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ, et al
. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73–83. Review.
14. Macdonald N, Elam G, Hickson F, Imrie J, McGarrigle CA, Fenton KA, et al
. Factors associated with HIV seroconversion in gay men in England at the start of the 21st century. Sex Transm Infect 2008; 84:8–13.
15. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al
. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403–1409.
16. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al
. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552–7557.
17. Kulkarni PS, Butera ST, Duerr AC. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative individuals. AIDS Rev 2003; 5:87–103. Review.
18. Varghese B, Maher JE, Peterman TA, Branson BM, Steketee RW. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 2002; 29:38–43.
19. Fisher M, Benn P, Evans B. UK guideline for the use of postexposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2006; 17:81–92.
20. Workshop on HIV transmission: HIV exposed and resistant NIH July 8–9th 2010 Washington DC.
21. Allard R. A family of mathematical models to describe the risk of infection by a sexually transmitted agent. Epidemiology 1990; 1:30–33.
22. Pinkerton SD, Abramson PR. Evaluating the risks: a Bernoulli process model of HIV infection and risk reduction. Evaluation Rev 1993; 17:504–528.
23. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, et al
. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. Lancet 2005; 366:1182–1188.
24. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al
. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643–656.
25. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, Taljaard D, et al
. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
26. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, et al
. Male circumcision for HIV prevention in men in Rakai, Uganda a randomised trial. Lancet 2007; 369:657–666.
27. Gray RH, Kigozi G, Serwadda D, Makumbi F, Nalugoda F, Watya S, et al
. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda
. Am J Obstet Gynecol
28. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687–693.
29. Fisher M, Pao D, Brown AE, Sudarshi D, Gill ON, Cane P, et al
. Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS 2010; 24:1739–1747.
30. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al
. Hormonal Contraception and the risk of HIV Acquisition (HC-HIV) Study Group 2007. AIDS 2007; 21:85–95.
31. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118–129.
32. Kapiga SH, Sam NE, Bang H, Ni Q, Ao TT, Kiwelu I, et al
. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J Infect Dis 2007; 195:1260–1269.
33. Kassler WJ, Zenilman JM, Erickson B, Fox R, Peterman TA, Hook EW 3rd. Seroconversion in patients attending sexually transmitted disease clinics. AIDS 1994; 8:351–355.
34. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, et al
. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863–1868.
35. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, et al
. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7:95–102.
36. McClelland RS, Sangare L, Hassan WM, Lavreys L, Mandaliya K, Kiarie J, et al
. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195:698–702.
37. Van Der Pol B, Kwok C, Pierre-Louis B, Rinaldi A, Salata RA, Chen PL, et al
. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 2008; 197:548–554.
38. Reynolds SJ, Risbud AR, Shepherd ME, Rompalo AM, Ghate MV, Godbole SV, et al
. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect 2006; 82:121–126.
39. Bichacz K, Patel P, Taylor M, Kerndt PR, Byers RH, Holmberg SD, Klausner JD. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients wit new syphilis infections. AIDS 2004; 15:2075–2079.
40. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, et al
. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991; 163:233–239.
41. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro K, et al
. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530–536.
42. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al
. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003; 361:645–652.
43. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, et al
, Kibera HIV Study Group. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291:2555–2562.
44. Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, et al
. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998; 12:1699–1706.
45. Myer L, Denny L, Telerant R, Souza M, Wright TC Jr, Kuhn L. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis 2005; 192:1372–1380.
46. Mayaud P, Gill D, Weiss H. The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sex Transm Infect 2001; 77:248–254.
47. Hester R, Kennedy S. Candida infection as a risk factor for HIV transmission. J Womens Health (Larchmt) 2003; 12:487–494.
48. Lazzarin A, Saracco A, Musicco M, Nicolosi A. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Arch Intern Med 1991; 151:2411–2416.
49. Richardson B, Otieno P, Mbori-Ngacha D. Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women. AIDS 2007; 21:749–753.
50. Wang C, Reilly M, Kreiss J. Risk of HIV infection in oral contraceptive pill users: a meta-analysis. J Acquir Immune Defic Syndr 1999; 21:51–58.
51. Grant RM, Wiley JA, Winkelstein W. Infectivity of the human immunodeficiency virus: estimates from a prospective study of homosexual men. J Infect Dis 1987; 156:189–193.
52. Samuel MC, Hessol N, Shiboski S, Engel RR, Speed TP, Winkelstein W Jr. Factors associated with human immunodeficiency virus seroconversion in homosexual men in three San Francisco cohort studies, 1984-1989. J Acquir Immune Defic Syndr 1993; 6:303–312.
53. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306–311.
54. DeGruttola V, Seage GR 3rd, Mayer KH, Horsburgh CR Jr. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989; 42:849–856.
55. De Vincenzi I, for the European Study Group in Heterosexual Transmission of HIV. A longitudinal study of human immunodeficiency virus transmission by heterosexual couples. N Engl J Med 1994; 331:341–346.
56. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88–96.
57. Shiboski S, Padian N. Epidemiologic evidence for time variation in HIV infectivity. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:527–535.
58. Downs AM, De Vincenzi I. Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. J Acquir Immune Defic Syndr Hum Retroviruses 1996; 11:388–395.
59. Wiley J, Herschkorn S, Padian N. Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse. Stat Med 1989; 8:93–102.
60. Padian N, Shiboski S, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA 1991; 266:1664–1667.
61. Cameron DW, Simonsen JN, D'Costa LJ, Ronald AR, Maitha GM, Gakinya MN, et al
. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; 2:403–407.
62. Mastro T, Kitayaporn D. HIV type 1 transmission probabilities: estimates from epidemiological studies. AIDS Res Human Retroviruses 1998; S3:S223–S227.
63. Peterman TA, Stoneburner RL, Allen JR, Jaffe HW, Curran JW. Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1988; 259:55–58.
64. del Romero J, Marincovich B, Castilla J, García S, Campo J, Hernando V, Rodríguez C. Evaluating the risk of HIV transmission through unprotected orogenital sex. AIDS 2002; 16:1296–1297.
65. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al
. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946–954.
66. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 2007; 104:17441–17446.
67. Mei Y, Wang L, Holte SE. A comparison of methods for determining HIV viral set point. Stat Med 2008; 27:121–139.
68. Pinkerton S, Holtgrave D, Leviton L, Wagstaff D, Abramson P. Model-based evaluation of HIV prevention interventions. Evaluation Rev 1998; 22:155–157.
69. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314–320.
70. Sturmer M, Doerr H, Berger A, Gute P. Is transmission of HIV-1 in nonviraemic serodiscordant couples possible? Antivir Ther 2008; 13:729–732.
71. Barreiro P, del Romero J, Leal M, and the Spanish HIV-Discordant Study Group. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:324–326.
72. Castilla J, Del Romero J, Hernando V, Marincovich B, Garcia S, Rodriguez C, et al
. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96–101.
73. Kimani J, Kaul R, Nagelkerke NJ, Luo M, MacDonald KS, Ngugi E, et al
. Reduced rates of HIV acquisition during unprotected sex by Kenyan female sex workers predating population declines in HIV prevalence. AIDS 2008; 22:131–137.
74. The INSIGHT Group. Partners of people on ART: a New Evaluation of the Risks (PARTNER study). NIHR Programme Grant for Applied Research: RP-PG-0608-10142 (2010-15).
75. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553–563.
76. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention
. Int J Epidemiol
77. Taylor S, Back DJ, Drake SM, Workman J, Reynolds H, Gibbons SE, et al
. Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. J Antimicrob Chemother 2001; 48:351–354.
78. Vernazza PL, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bulletin des médecins suisses 2008; 89:165–169.
79. HIV prevention trials network. HPTN 052: a randomized placebo-controlled trial to evaluate the effectiveness of antiretroviral therapy to prevent the sexual transmission of HIV-1 in serodiscordant couples. http://www.hptn.org/research_studies/hptn052.asp
80. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 1994; 2:229–243.
81. O'Brien TR, Busch MP, Donegan E, Ward JW, Wong L, Samson SM, et al
. Heterosexual transmission of human immunodeficiency virus type 1 from transfusion recipients to their sex partners. J Acquir Immune Defic Syndr 1994; 7:705–710.
82. European study group. Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV
83. Seidlin M, Vogler M, Lee E, Lee YS, Dubin N. Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS 1993; 7:1247–1254.
84. Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JC. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 2010; 24:907–913.
85. Royce RA, Seña A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336:1072–1078.
86. Zunzunegui V, Casabona J, Laguna J, Tor J, Ortiz C, Alameda J, González Lahoz J. Risk factors for the heterosexual transmission of HIV from man to woman: a Spanish multicenter study. Med Clin (Barc) 1992; 98:721–725.
87. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al
. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 71:2109–2119.
88. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al
, HSV trial team; Steering and Data Monitoring Committees. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560–1571.
89. Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L. ANRS 1285 Study Group Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790–799.
90. Cowan FF, Pascoe SJ, Barlow KL, Langhaug LF, Jaffar S, Hargrove JW. Association of genital shedding of herpes simplex virus type 2 and HIV-1 among sex workers in rural Zimbabwe. AIDS 2006; 20:261–267.
91. Donnelly C, Leisenring W, Kanki P, Awerbuch T, Sandberg S. Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal
. Bull Math Biol
92. Wang CC, McClelland RS, Overbaugh J, Reilly M, Panteleeff DD, Mandaliya K, et al
. The effect of hormonal contraception on genital tract shedding of HIV-1